Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amphetamine Sulfate
Therapeutic Area: Psychiatry/Psychology Product Name: TRN-110
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2021
Details:
Results from the study, “Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Evaluate the Efficacy and Safety of the Amphetamine Extended-Release Tablet in Adults with Attention-Deficit/Hyperactivity Disorder,” were reported during the annual APSARD meeting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Seltorexant
Therapeutic Area: Psychiatry/Psychology Product Name: MIN-202
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Royalty Pharma
Deal Size: $155.0 million Upfront Cash: $60.0 million
Deal Type: Acquisition January 19, 2021
Details:
Royalty Pharma will acquire Minerva’s royalty interest in seltorexant. Seltorexant is currently in Phase 3 development for the treatment of major depressive disorder (MDD) with insomnia symptoms by Janssen Pharmaceutica, N.V., a subsidiary of Johnson & Johnson.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Naltrexone,Bupropion
Therapeutic Area: Psychiatry/Psychology Product Name: Vivitrol
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2021
Details:
This is the second published study evaluating efficacy and safety of naltrexone for extended-release injectable suspension plus oral extended-release bupropion administered daily as a combination treatment methamphetamine use disorder.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Naltrexone,Bupropion
Therapeutic Area: Psychiatry/Psychology Product Name: Vivitrol
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
Details:
A combination of two medications, injectable naltrexone and oral bupropion, was safe and effective in treating adults with moderate or severe methamphetamine use disorder in a double-blind, placebo-controlled Phase III clinical trial.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
